KR100843155B1 - Double-stabilized Vitamin C-containing skin whitening cosmetic composition - Google Patents
Double-stabilized Vitamin C-containing skin whitening cosmetic composition Download PDFInfo
- Publication number
- KR100843155B1 KR100843155B1 KR1020060119757A KR20060119757A KR100843155B1 KR 100843155 B1 KR100843155 B1 KR 100843155B1 KR 1020060119757 A KR1020060119757 A KR 1020060119757A KR 20060119757 A KR20060119757 A KR 20060119757A KR 100843155 B1 KR100843155 B1 KR 100843155B1
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- cosmetic composition
- cream
- whitening cosmetic
- lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 137
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 229930003268 Vitamin C Natural products 0.000 title claims abstract description 63
- 235000019154 vitamin C Nutrition 0.000 title claims abstract description 63
- 239000011718 vitamin C Substances 0.000 title claims abstract description 63
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 239000002537 cosmetic Substances 0.000 title claims abstract description 26
- 230000002087 whitening effect Effects 0.000 title claims abstract description 21
- PDHAOJSHSJQANO-OWOJBTEDSA-N Oxyresveratrol Chemical compound OC1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 PDHAOJSHSJQANO-OWOJBTEDSA-N 0.000 claims abstract description 26
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 20
- 239000000787 lecithin Substances 0.000 claims abstract description 20
- 235000010445 lecithin Nutrition 0.000 claims abstract description 20
- 229940067606 lecithin Drugs 0.000 claims abstract description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
- 239000001301 oxygen Substances 0.000 claims abstract description 9
- 230000001590 oxidative effect Effects 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims abstract description 6
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 230000003647 oxidation Effects 0.000 claims abstract description 5
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 5
- 230000000903 blocking effect Effects 0.000 claims abstract description 4
- 239000003381 stabilizer Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000006071 cream Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 229960004063 propylene glycol Drugs 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- -1 pack Substances 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims 1
- 125000000962 organic group Chemical group 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 8
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000019612 pigmentation Effects 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 이중으로 안정화된 비타민C 함유 미백 화장료 조성물에 관한 것으로서,The present invention relates to a double stabilized vitamin C-containing whitening cosmetic composition,
상세하게는 수용액상의 비타민 C에 활성산소의 접근을 차단키 위한 산화안정제로 옥시레스베라트롤(Oxyresveratrol)을 사용하여 활성산소의 비타민C에 접근을 차단시켜 비타민C 의 산화 안정성을 증가 시킨 후, 이차적으로는 안정한 용액을 레시틴(Lecithin)-오르가노겔(Organo Gel)구조로 감싸게 하여 비타민C 를 더욱 안정화 하여 효과적인 미백 화장료를 제공하고자 한다.Specifically, oxyresveratrol was used as an oxidative stabilizer to block the access of active oxygen to vitamin C in aqueous solution, thereby increasing the oxidation stability of vitamin C by blocking access to vitamin C of active oxygen. The stable solution is wrapped in a lecithin-organo gel structure to further stabilize vitamin C to provide an effective whitening cosmetic.
비타민C, 옥시레스베라트롤, 레시틴, 오르가노 겔, 미백 Vitamin C, Oxyresveratrol, Lecithin, Organo Gel, Whitening
Description
본 발명은 수중에서 불안정한 비타민C를 안정되게 유지키 위한 미백 화장료 조성물에 관한 것으로서 구체적으로 말하면, 일차적으로는 수용액상의 비타민 C에 활성산소의 접근을 차단키 위한 산화안정제로 옥시레스베라트롤(Oxyresveratrol)을 사용하여 비타민C의 산화 안정성을 증가시킨 후 이차적으로 상기 일차적으로 안정화된 용액을 레시틴(Lecithin)-오르가노겔(Organo Gel)구조로 감싸게 하여 비타민C 를 더욱 안정화 하여 효과적인 미백 화장료를 제공 하고자 하는 이중으로 안정화된 비타민C 함유 피부 미백 화장료 조성물에 관한 것이다.The present invention relates to a whitening cosmetic composition for stably maintaining unstable vitamin C in water. Specifically, the present invention primarily uses oxyresveratrol as an oxidative stabilizer to block the access of active oxygen to vitamin C in aqueous solution. In order to increase the oxidation stability of vitamin C, the secondary stabilized solution is secondly wrapped in a lecithin-organo gel structure to further stabilize vitamin C to provide an effective whitening cosmetic. A stabilized vitamin C-containing skin whitening cosmetic composition.
표피, 진피, 피하지방으로 구성되어 있는 피부는 인체를 이루고 있는 가장 큰 기관으로 보호기능과 장벽기능, 온도조절기능, 배설기능, 호흡 기능 등 다양한 역할을 감당하고 있는 아주 중요한 기관이다. 하지만 나이가 들면서 피부의 기능은 급격하게 저하되고 이로 인한 다양한 변화가 오면서 노화되어 가는데, 피부의 두께 가 얇아지고, 피부장벽의 기능이 급격하게 저하되어 피부의 수분함량이 떨어지고 피부가 건조해질 뿐만 아니라 다양한 피부 병변을 유발한다. 특별히, 자외선량의 증가와 대기오염 및 현대인의 과도한 피로와 스트레스 등으로 인한 반응성이 높은 활성산소, 자유라디칼의 생성은 생체성분(단백질, 핵산, 세포막 지질 등)을 산화시키거나 변성시켜 피부노화의 주원인으로 작용한다. 피부노화에 따른 주름형성, 피부 탄력감소, 색소침착 등은 화장료 영역에서도 피부 보호 및 미용 차원에서 중요한 과제로 가장 많이 연구되어 지고 있다.The skin, which consists of the epidermis, the dermis, and the subcutaneous fat, is the largest organ that makes up the human body. However, as the skin ages, the function of the skin sharply deteriorates and various changes are aging. The thickness of the skin becomes thinner, the function of the skin barrier sharply deteriorates, so that the moisture content of the skin decreases and the skin dries. Causes various skin lesions. In particular, the production of highly reactive free radicals and free radicals due to the increase in the amount of ultraviolet rays, air pollution, and excessive fatigue and stress of modern people, oxidizes or denatures biological components (proteins, nucleic acids, cell membrane lipids, etc.) It acts as the main cause. Wrinkle formation, skin elasticity reduction and pigmentation due to skin aging have been studied as the most important issues in skin care and cosmetics.
이미, 피부과 영역에서 피부주름 및 기미, 색소침착 개선을 위해 널리 사용되고 있는 비타민 A인 레티놀(retinol)은 화장료로도 널리 이용되어 레티놀 함유 화장료가 일광에 의해 형성된 피부주름이나 피부처짐, 탄력감소 등을 효과적으로 개선한 임상 결과들이 보고되고 있고, 미국 특허 4,603,146 및 4,877,805에서 콜라겐 합성과 분해억제에 효과적인 레티놀을 이용한 주름개선효과를 제시하였다. 콜라겐 합성에 의한 주름개선은 L-ascorbic acid(비타민 C)를 함유하는 화장료 조성물도 효과적이며 이는 피부주름개선 이외 생체 내에서 항산화 효과 및 자외선차단, 기미/주근깨/검버섯 등의 색소침착 등에 효과적이다 라는 보고가 있다.(미국특허 제4,938,969호/ 미국특허 제4,772,591호/유럽특허 제0533667호) Retinol, a vitamin A that is already widely used in dermatology to improve skin wrinkles, blemishes and pigmentation, is also widely used as a cosmetic agent, and retinol-containing cosmetics can reduce wrinkles, sagging and elasticity caused by sunlight. Effective clinical results have been reported, and US Pat. Nos. 4,603,146 and 4,877,805 have suggested an anti-wrinkle effect using retinol which is effective for collagen synthesis and degradation inhibition. Wrinkle improvement by collagen synthesis is also effective in the cosmetic composition containing L-ascorbic acid (vitamin C), which is effective in anti-oxidation effect and anti-pigmentation, pigmentation such as blemishes, freckles, and black mushrooms, in addition to skin wrinkle improvement. There is a report. (U.S. Patent No. 4,938,969 / U.S. Patent No. 4,772,591 / European Patent No.0533667)
피부는 자연노화 되기도 하나 자연환경에 의하여 특히 광노화에 의해 주름이 생기고 탄력이 저하되고, 거칠어지고 건조해지며 기미,주근깨 등이 발생하여 미용상 보기가 좋지 않게 변한다.Although the skin is natural aging, wrinkles, elasticity, roughness and dryness, blemishes and freckles occur due to natural aging, especially by photoaging, resulting in a poor cosmetic appearance.
비타민C 는 생체내에서 다양한 생리작용을 통하여 이러한 노화 현상을 억제 하거나 개선하는데 뛰어난 효과가 있어 오래전부터 식품, 의료용 혹은 화장품에 응용되고 있다.Vitamin C has been applied to food, medical or cosmetics for a long time since it has an excellent effect on suppressing or improving such aging through various physiological functions in vivo.
비타민C의 기능을 간단히 살펴 보면 비타민C는 프롤릴히드록시화제의 활성을 촉진하여 히드록시 프롤린 생합성을 촉진하여 삼중나선 구조인 콜라겐 생합성을 촉진 함으로서 피부주름 개선 효과를 준다. 비타민C는 UVA에 대한 자외선 차단 기능이 강하고 UVB로 인해 발생한 홍반 및 부종을 감소시킨다. 또한 비타민C는 피부, 혈액 및 기타 조직에서 강력한 생체 항산화제로 작용하는데 반응성이 높은 활성산소, 자유 라디칼, 및 과산화물에 의하여 생체 성분이 산화 되거나 변성 되는 것을 방지 함으로서 피부노화의 원인을 차단하는 항산화 효과를 갖고 있다. 아울러 비타민 C는 색소침착억제 효과를 갖는데 이는 멜라닌색소형성 억제 효과를 갖기 때문이다.Looking briefly at the function of vitamin C, vitamin C promotes the activity of the prolyl hydroxylating agent to promote hydroxy proline biosynthesis, thereby promoting collagen biosynthesis, a triple helix structure, thereby improving skin wrinkles. Vitamin C is highly resistant to UVA and reduces erythema and edema caused by UVB. Vitamin C also acts as a powerful bio-oxidant in skin, blood and other tissues. It prevents the oxidation and degeneration of biological components by highly reactive free radicals, free radicals, and peroxides. Have In addition, vitamin C has a pigmentation inhibitory effect, because it has a melanin pigmentation inhibitory effect.
그러나 이렇듯 다양한 효과를 갖는 비타민C 는 열, 빛, 산소 등에 매우 불안정하여 대기중에 노출되거나 수용액 중에서 쉽게 산화되어 역가가 떨어지고, 변색, 변취가 일어나는 등 안정성 및 안정성에 큰 문제점을 갖고있어 그동안 다양한 비타민 C 유도체들이 연구되어 사용되어져 왔으나 이 또한 효율면에서 순수 비타민C 보다 열등한 문제점을 갖고있다.However, vitamin C, which has various effects like this, is very unstable in heat, light, oxygen, etc., so it is exposed to the atmosphere or easily oxidized in aqueous solution, which lowers its titer, discoloration, and odor. Derivatives have been studied and used, but they also have inferior problems with pure vitamin C in terms of efficiency.
최근에는 비타민C가 여러가지 불안정한 문제점을 가지고 있지만 또한 여러가지 생리적 기능에 장점을 가지고 있어 불안정한 비타민C를 안정화하는 제형연구가 다각도로 진행 되고 있다. Recently, vitamin C has a variety of unstable problems, but also has a number of physiological functions have been studied in various forms to stabilize the unstable vitamin C.
예를들면 글루코닉산 혹은 우로카닉산과의 화학적 회합체를 만들거나, 사이클로덱스트린, 지오라이트, 리포좀등에 함입시키는 물리적 기술을 이용하기도 하였다. 또 다른 방법으로는 비타민C를 코팅하는 방법등이 제시되기도 하였다. 그러나 이런 방법들은 효율면에서 충분한 안정도를 보이지 않았을 뿐더러, 어떤 경우에는 화장료의 제형으로 적합하지 못했다.For example, they used chemical techniques to make chemical associations with gluconic or uronic acids or to incorporate them into cyclodextrins, geolites, liposomes, and the like. As another method, a method of coating vitamin C has been suggested. However, these methods did not show sufficient stability in terms of efficiency, and in some cases were not suitable for cosmetic formulations.
한편 비타민E를 비롯한 여러가지 항산화제를 도입하여 안정화하고자 하는 연구도 시도 되었지만 변취, 변색등의 문제점을 해결할 수는 없었다.(미국특허 제 4938969호)On the other hand, a study to stabilize by introducing various antioxidants, including vitamin E, was attempted, but problems such as odor and discoloration could not be solved. (US Patent No. 4938969)
이에 본 발명자들은 비타민C가 가지고 있는 안정성의 문제점을 해결하고자 연구를 거듭한 결과 제형내에서 비타민C의 산화 안정성을 증대하기 위해 강력한 항산화제를 사용하고, 레시틴 오르가노겔 제형내에 비타민C를 포집하여 결합수의 양을 증대하여 비타민C의 이온 활동도를 감소함으로써 비타민C를 효과적으로 안정화 할 수 있었다.Therefore, the present inventors conducted a study to solve the stability problem of vitamin C, using a powerful antioxidant to increase the oxidative stability of vitamin C in the formulation, and by collecting vitamin C in the lecithin organogel formulation By increasing the amount of bound water, vitamin C could be effectively stabilized by reducing the ion activity of vitamin C.
따라서 본 발명의 목적은 안정화된 비타민C 함유 미백 화장료 조성물을 제공 하는데 있다.Accordingly, an object of the present invention is to provide a stabilized vitamin C-containing whitening cosmetic composition.
본 발명의 상기 목적을 달성하기 위한 구체적인 해결적 수단은, Specific solution means for achieving the above object of the present invention,
[수용액상의 비타민 C에 활성산소의 접근을 차단키 위한 산화안정제로 옥시레스베라트롤(Oxyresveratrol)을 사용하여 활성산소의 비타민C에 접근을 차단시켜 비타민C의 산화 안정성을 증가시킨 후, 상기 용액에 레시틴(Lecithin)-오르가노겔(Organo Gel)구조인 레시틴겔로 감싸게 한 것과,[Oxyresveratrol is used as an oxidative stabilizer to block the access of active oxygen to vitamin C in aqueous solution to block the access to vitamin C of active oxygen to increase the oxidative stability of vitamin C. Wrapped with lecithin)-organo gel structure lecithin gel,
상기 비타민C 는 전체 조성물 100% 대비 0.1 ~ 20%이며, 옥시레스베라트롤은 0.05 ~ 10%로 이루어진 것과,The vitamin C is 0.1 to 20% compared to 100% of the total composition, oxyresveratrol is made of 0.05 to 10%,
상기 레시틴겔은 포스파티딜콜린(Phosphatidylcholine,Lipoid S100-3) 6g, 에탄올 10g, MCT(Medium chain triglyceride) 10g, PG(Propyleneglycol) 54.0g, 옥시레스베라트롤 2.0g 이 용해된 용액에 비타민C 5g과 물 15g이 용해된 총20g의 물 을 첨가하여 실온에서 교반하여 제조된 것과,The lecithin gel is dissolved in 5g of vitamin C and 15g of water in a solution in which 6g of phosphatidylcholine (Lipoid S100-3), 10g of ethanol, 10g of MCT (Medium chain triglyceride), 54.0g of PG (Propyleneglycol), and 2.0g of oxyresveratrol are dissolved. A total of 20 g of water, stirred at room temperature,
상기 화장료 조성물은 유연화장수, 수렴화장수, 영양화장수, 아이크림, 영양크림, 맛사지크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 엣센스로 구성된 군으로부터 선택되는 어느 하나의 제형을 갖는 것]을 그 구성적 특징으로 함으로서 상기의 목적을 달성할 수 있다.The cosmetic composition is one having a formulation selected from the group consisting of supple cosmetics, astringent cosmetics, nourishing cosmetics, eye cream, nutrition cream, massage cream, cleansing cream, cleansing foam, cleansing water, packs, essences] The above object can be achieved by the constitutional features.
상기한 목적을 달성하기 위하여 본 발명에 따른 항산화제는 옥시레스베라트롤을 사용하였다. 옥시레스베라트롤은 일반적으로 알려진 레스베라트롤보다 훨씬 강력항 항산화제로서 뽕나무에서 추출하여 사용하였다. 한편 옥시레스베라트롤은 멜라닌을 형성하는데 관여하는 티로시나제를 강력히 저해하는데, 비타민C 와함꼐 사용하면 피부미백에 대한 상승효과를 기대 할수있다.In order to achieve the above object, an antioxidant according to the present invention used oxyresveratrol. Oxyresveratrol is a much more potent antioxidant than commonly known resveratrol. Oxyresveratrol, on the other hand, strongly inhibits tyrosinase, which is involved in the formation of melanin, and when used in conjunction with vitamin C, synergistic effects on skin whitening can be expected.
오르가노겔은 대표적으로 젤라틴겔과 레시틴겔이 알려져 있다. 이들겔은 물/오일 마이크로에멀젼(water in oil) 계로 이루어져 있어 수용성인 비타민C를 겔내에서 안정화 할 수 있는 최적의 시스템이다. 본연구에서는 레시틴 겔을 사용하였으며, 적절하게 만들어진 비타민C 함유 레시틴 겔은 제조물내에 자유수의 존재를 감소시키고 결합수의 양을 증대하는 피부유사 구조를 갖고있어, 비타민C의 이온 활동도를 감소시킬 뿐만 아니라 활성산소가 비타민C로 접근하는 것을 차단 함으로써 비타민C의 산화 안정성이 증대 된다. Organogels are typically known as gelatin gels and lecithin gels. These gels consist of a water / oil microemulsion (water in oil) system, which is the optimal system to stabilize the water-soluble vitamin C in the gel. In this study, lecithin gels were used, and properly formulated vitamin C-containing lecithin gels have a skin-like structure that reduces the presence of free water and increases the amount of bound water in the preparation, thus reducing the ion activity of vitamin C. In addition, oxidative stability of vitamin C is increased by blocking free radicals from accessing vitamin C.
한편 비타민C 함유 레시틴 겔을 이용하여 미백 화장료에 적용하였을 때 수중의 활성 산소의 접근을 차단하여 비타민c 의 산화 안정성이 향상 되었고, 미백효과도 우수함을 보였다. 이하 실시예, 처방예, 비교예 및 실험예를 들어 본 발명의 구성 및 효과를 상세히 설명 한다. 그러나 본 발명이 이들에 한정 되는 것은 아니다. On the other hand, when applied to whitening cosmetics using vitamin C-containing lecithin gel, the oxidation stability of vitamin c was improved by blocking the access of active oxygen in water, and the whitening effect was also excellent. For the following examples, prescription examples, comparative examples and experimental examples will be described in detail the configuration and effect of the present invention. However, the present invention is not limited to these.
[실시예] 비타민C 를 안정화한 레시틴 겔 만들기EXAMPLES Making Lecithin Gels with Stabilized Vitamin C
포스파티딜콜린(Phosphatidylcholine,Lipoid S100-3) 6g, 에탄올 10g, MCT(Medium chain triglyceride) 10g, PG(Propyleneglycol) 54.0g, 옥시레스베라트롤 2.0g 이 용해된 용액에 비타민C 5g과 물 15g이 용해된 총20g의 물을 첨가하여 실온에서 교반하여 레시틴 겔을 만들었다.A total of 20g of vitamin C and 15g of water dissolved in 6g of phosphatidylcholine (Lipoid S100-3), 10g of ethanol, 10g of medium chain triglyceride (MCT), 54.0g of PG (Propyleneglycol), and 2.0g of oxyresveratrol Water was added and stirred at room temperature to make lecithin gels.
처방예 1. 레시틴겔(실시예 1)을 함유하는 영양크림의 처방예는 다음과 같다.Prescription Example 1. A prescription example of a nourishing cream containing lecithin gel (Example 1) is as follows.
비교예 1.Comparative Example 1.
레시틴겔 대신 안정화 하지 않은 비타민C를 처방예 1)에 따라 제조한 조성물Composition prepared according to Formulation Example 1) with vitamin C not stabilized in place of lecithin gel
실험예 1. 비타민C의 역가 측정Experimental Example 1. Measurement of the titer of vitamin C
상기 처방예 1) 과 비교예 1) 에서 조성물내의 비타민C의 초기 역가를 100으로 하고, 1개월후의 비타민C 역가를 25℃ 와 45℃ 에서 측정하여 그 결과를 표 1)에 나타 내었다.In Formulation Example 1) and Comparative Example 1), the initial titer of vitamin C in the composition was 100, and the vitamin C titer after one month was measured at 25 ° C and 45 ° C, and the results are shown in Table 1).
표 1. 비타민 C 의 역가 비교결과 Table 1. Comparison of titers of vitamin C
상기표에서 보듯이, 비타민C 를 레시틴겔로 안정화한 제형(실시예 1)이 그렇지 않은 제형(비교예 1) 보다 시간의 경과에 따라 훨씬 안정함을 알수있다.As shown in the table, it can be seen that the formulation stabilized with lecithin gel vitamin C (Example 1) is much more stable over time than the formulation (Comparative Example 1).
실험예 2. 임상 실험에 의한 미백효과 측정Experimental Example 2 Measurement of Whitening Effect by Clinical Experiment
1) 실험방법: 본발명의 화장료의 임상미백 효능 실험을 하기 위해서 기미, 주근깨 및 색소 침착증을 가지고 있는 건강한 성인 남녀 20명을 무작위로 A, B 두개그룹으로 나누었다. A 그룹에는 비타민C 를 안정화시킨 레시틴 겔을 함유하는 처방예 1)을 B 그룹에는 비교예 1)을 적용하여 각각 1일 2회씩 12주간 도포한후 피부색의 변화를 크로마메터(Minolta CR300)기기를 이용하여 색의 밝기변화( ΔL)를 측정하고, 복수의 숙련자에 의한 객관적 육아 관찰과 피검자에 의한 주관적 육안적 관찰을 실시하여 하기 등급의 분류에 따라 효과를 측정 하였다. 그결과를 하기 표 2) 에 나타내었다. 이때 미백 효능 정도를 다음의 7등급으로 분류하여 평가 하였다.1) Method: To test the clinical whitening efficacy of cosmetics of the present invention, 20 healthy men and women with blemishes, freckles and pigmentation were randomly divided into two groups A and B. Prescription Example 1) containing lecithin gel stabilized with vitamin C was applied to Group A, and Comparative Example 1) was applied to Group B, twice a day for 12 weeks. The change of brightness (ΔL) of color was measured, and objective parenting observation by a plurality of skilled workers and subjective visual observation by a subject were measured, and effects were measured according to the following classification. The results are shown in Table 2). At this time, the degree of whitening efficacy was classified into the following seven ratings.
미백효능 평가 기준: -3:매우악화, -2:악화, -1:약간 악화, 0:변화없음, 1:약간개선, 2:개선, 3:매우개선Evaluation criteria for whitening efficacy: -3: Very aggravated, -2: Aggravated, -1: Slightly worsened, 0: No change, 1: Slightly improved, 2: Improved, 3: Very improved
2) 실험결과2) Experiment result
표 2. 미백효과에대한 임상결과Table 2. Clinical Results for Whitening Effects
상기표 2)에서 보듯이, 본발명의 비타민C 를 안정화 시킨 제형의 제품을 도포한 A 그룹이 그렇지않은 제품을 도포한 B그룹에 비해 3가지평가에서 모두 우수한 미백 임상효과가 있음을 알수있다.As shown in Table 2), it can be seen that the group A applied the product of the vitamin C stabilized formulation of the present invention has excellent whitening clinical effect in all three evaluations compared to the group B applied to the product not applied.
본 발명에 의하면 비타민C를 옥시레스베라톨과 레시틴겔로서 안정화 함으로써 제품내에서 비타민C 의 산화 안정성을 상당히 향상 시킬수 있으며 변색,변취도 발생하지 않아 화장료 및 의약품 용도로 사용가능한 조성물을 제공할 수 있다.According to the present invention, by stabilizing vitamin C as oxyresveratol and lecithin gel, it is possible to significantly improve the oxidative stability of vitamin C in the product and to provide a composition that can be used for cosmetics and pharmaceuticals as it does not cause discoloration or odor. .
이상에서는 본 발명을 특정의 바람직한 실시예를 예를들어 도시하고 설명하였으나, 본 발명은 상기한 실시예에 한정되지 아니하며 본 발명의 정신을 벗어나지 않는 범위내에서 당해 발명이 속하는 기술분야에서 통상의 지식을 가진자에 의해 다양한 변경과 수정이 가능할 것이다.In the above, the present invention has been illustrated and described with reference to specific preferred embodiments, but the present invention is not limited to the above-described embodiments and is not limited to the spirit of the present invention. Various changes and modifications can be made by those who have
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060119757A KR100843155B1 (en) | 2006-11-30 | 2006-11-30 | Double-stabilized Vitamin C-containing skin whitening cosmetic composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060119757A KR100843155B1 (en) | 2006-11-30 | 2006-11-30 | Double-stabilized Vitamin C-containing skin whitening cosmetic composition |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080049328A KR20080049328A (en) | 2008-06-04 |
KR100843155B1 true KR100843155B1 (en) | 2008-07-02 |
Family
ID=39805125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060119757A Expired - Fee Related KR100843155B1 (en) | 2006-11-30 | 2006-11-30 | Double-stabilized Vitamin C-containing skin whitening cosmetic composition |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100843155B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2013081120A1 (en) * | 2011-11-30 | 2015-04-27 | 学校法人日本大学 | Lecithin organogel former |
KR20200092709A (en) * | 2019-01-25 | 2020-08-04 | 제주대학교 산학협력단 | Pluronic Lecithin Organogel composition with improved storage stability at low temperature |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101461121B1 (en) * | 2013-02-12 | 2014-11-12 | (주)아비오 | High concentrations of vitamin C and derivatives of transparent sol, gel composition |
CN104824135B (en) * | 2015-05-12 | 2018-05-04 | 江南大学 | Oxidized resveratrol micro emulsion and preparation method and application |
KR102551196B1 (en) | 2023-01-25 | 2023-07-04 | (주)페르스 | Manufacturing method of whitening cosmetic composition with stabilized pure vitamin C |
KR102551199B1 (en) | 2023-01-25 | 2023-07-04 | (주)페르스 | Manufacturing method of high-concentration vitamin C cosmetic composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06256150A (en) * | 1993-03-01 | 1994-09-13 | Maruzen Pharmaceut Co Ltd | Skin cosmetic |
JP2001008722A (en) * | 1999-06-30 | 2001-01-16 | Matsuo Kaban:Kk | Hanger |
US6440433B1 (en) | 1999-07-02 | 2002-08-27 | Societe L'oreal S.A. | Hydroxystilbene/ascorbic acid compositions for treating skin afflictions |
KR100731613B1 (en) | 2006-01-12 | 2007-06-22 | 코스맥스 주식회사 | Whitening and anti-aging cosmetic composition comprising a mulberry stem heartwood extract |
-
2006
- 2006-11-30 KR KR1020060119757A patent/KR100843155B1/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06256150A (en) * | 1993-03-01 | 1994-09-13 | Maruzen Pharmaceut Co Ltd | Skin cosmetic |
JP2001008722A (en) * | 1999-06-30 | 2001-01-16 | Matsuo Kaban:Kk | Hanger |
US6440433B1 (en) | 1999-07-02 | 2002-08-27 | Societe L'oreal S.A. | Hydroxystilbene/ascorbic acid compositions for treating skin afflictions |
KR100731613B1 (en) | 2006-01-12 | 2007-06-22 | 코스맥스 주식회사 | Whitening and anti-aging cosmetic composition comprising a mulberry stem heartwood extract |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2013081120A1 (en) * | 2011-11-30 | 2015-04-27 | 学校法人日本大学 | Lecithin organogel former |
KR20200092709A (en) * | 2019-01-25 | 2020-08-04 | 제주대학교 산학협력단 | Pluronic Lecithin Organogel composition with improved storage stability at low temperature |
KR102184802B1 (en) | 2019-01-25 | 2020-12-01 | 제주대학교 산학협력단 | Pluronic Lecithin Organogel composition with improved storage stability at low temperature |
Also Published As
Publication number | Publication date |
---|---|
KR20080049328A (en) | 2008-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8802117B2 (en) | Melatonin and immunostimulating substance-based compositions | |
JPWO2004016236A1 (en) | Cosmetics | |
KR101769419B1 (en) | Multifunctional nourishing cream composition and preparing method of the same | |
KR100843155B1 (en) | Double-stabilized Vitamin C-containing skin whitening cosmetic composition | |
CN104352385A (en) | anti aging serum | |
KR20130088912A (en) | Skin external composition containing tangeretin and egcg | |
KR102142311B1 (en) | Skin external composition comprising tangeretin | |
CN104352382A (en) | Essence | |
KR101716489B1 (en) | Cosmetic composition containing sageretia theezans extracts | |
JPH0892057A (en) | Cosmetic blended with extract of seed of coffee tree | |
KR101915655B1 (en) | Cosmetic composition containing Croton Lechleri resin extract | |
KR20190071250A (en) | Composition for whitening and moisturizing skin | |
ES2668397T3 (en) | Compositions comprising vitamin C | |
JP2009137874A (en) | Lecithin gel comprising vitamin c (ascorbic acid), and method for producing the same | |
CN104352384A (en) | Serum with anti-aging benefits | |
KR100638137B1 (en) | Cosmetic composition containing extract of fern | |
CN103494737A (en) | Cosmetic preparation using ginger flower as anti-ageing and skin-protecting factor and preparation method of cosmetic preparation | |
KR101151008B1 (en) | Cosmetic composition containing phytantriol and hexamidine diisethionate for improving acnes | |
KR20100030453A (en) | Cosmetic composition containing a pine bark extract | |
CN113693966A (en) | Innovative whitening brightening freckle-removing cream and preparation method thereof | |
KR20070089327A (en) | Cosmetic composition for skin whitening | |
KR20210025339A (en) | A COSMETIC COMPOSITION FOR ACNE SKIN CARE COMPRISING Phloretin, Protaetiamycine AND Highly stabilized epidermal growth factor AS EFFECTIVE COMPONENT | |
KR102780293B1 (en) | Cosmetic composition comprising Actinidia fruit extract, actinidia flower extract and actinidia stem extract, and method for manufacturing the same | |
KR20130089559A (en) | Anti-aging composition | |
KR100424726B1 (en) | Skin care cosmetic composition containing stabilized vitamin C and phytosphingosine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20061130 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20071031 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20080328 |
|
PG1501 | Laying open of application | ||
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20080626 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20080626 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20110621 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20110621 Start annual number: 4 End annual number: 4 |
|
LAPS | Lapse due to unpaid annual fee | ||
PC1903 | Unpaid annual fee |